SOURCE: Ingen Technologies, Inc.
RIVERSIDE, CA--(Marketwire - Aug 7, 2012) - Ingen Technologies, Inc. (PINKSHEETS: IGNT), an emerging medical device manufacturer with proprietary medical products for the growing $4B respiratory markets, announced today that the company has agreed to deliver approximately 8,000 Oxyview units in value of $160,000.
The first purchase order will include the reuseable Oxyview oxygen flow meter model 203A and 206A; and the disposable adult-size Smart Nasal Cannula. The company currently has 80,000 units in stock and will meet demands from the National Distributor over the next few months. Ingen has the manufacturing processes and tooling capabilities to produce 100,000 Oxyview units on a monthly basis, in value of $2M.
"In the US alone, there are over 30 million patients diagnosed with Chronic Obstructive Pulmonary Disease, and the majority of these patients require home oxygen therapy. The disposable Smart Nasal Cannula and the Oxyview will be introduced to the majority of these patients through the national distributor and large medical service providers," stated Gary Tilden, Chairman.
WATCH THE PRODUCT VIDEO TO LEARN ABOUT OXYVIEW: www.otcfn.com/ignt/
FOR MORE UPDATED INFORMATION USE THE FOLLOWING LINK: www.otcfn.com/ignt/
LISTEN TO INGEN'S CHAIRMAN INTERVIEW AT: http://smallcapvoice.com/blog/7-24-12-smallcapvoice-interview-with-ingen-technologies-inc-pink-sheets-ignt
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.